Enanta Pharmaceuticals Inc (ENTA) reported quarterly earnings results on Monday, May-9-2016. The company reported $-0.09 earnings per share for the quarter, missing the analyst consensus estimate by $-0.19. Analysts had a consensus of $0.10. The company posted revenue of $13.00 million in the period, compared to analysts expectations of $16.80 million. The company’s revenue was down -77.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.49 EPS.
Many Wall Street Analysts have commented on Enanta Pharmaceuticals Inc. Enanta Pharmaceuticals Inc was Downgraded by JMP Securities to ” Mkt Perform” on Apr 28, 2016.
Enanta Pharmaceuticals Inc closed down -0.06 points or -0.24% at $24.97 with 3,06,285 shares getting traded on Friday. Post opening the session at $24.91, the shares hit an intraday low of $24.3 and an intraday high of $25.1 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Feb 17, 2016, Terry Vance (director) purchased 2,000 shares at $27.04 per share price. According to the SEC, on Nov 25, 2015, Paul J Mellett (Treasurer and CFO) sold 6,000 shares at $31.23 per share price. On Aug 11, 2015, Yat Sun Or (Chief Scientific Officer) sold 3,750 shares at $42.96 per share price, according to the Form-4 filing with the securities and exchange commission.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.